Our Technology

The MD Turbo® uses proprietary i-Point™ inhalation technology to trigger the release of medication from inhalers for delivery into the pulmonary tract. 

The mechanism is triggered by the patient's inhalation at 30 to 60 liters per minute. This is within the range (18 to 64 L/min) in which maximal bronchodilation and enhanced particle delivery to the lungs has been shown to occur. (1) This is also well below the mean peak inspiratory rate achievable by most asthma sufferers. (2&3)

The technology is designed to deliver medication in a more consistent manner than is typical with standard pMDIs alone. The technique required for use of standard pMDIs, by themselves, involves the manual actuation of the inhaler as the patient inhales. Any technique that is less than optimal can result in decreased drug delivery and potentially reduced efficacy. (4) 

This technology has the potential to make pMDIs a more attractive option to a broader range of patients, including those with arthritis and ailments causing loss of muscle tone or control.

May offer a practical alternative to holding chambers, for which many patients receive prescriptions but either misuse, never use or simply never obtain.

Patents & Trademarks

MD Turbo® is covered by a number of patents in the US as well as around the world. Our product is patented in the US, Australia, Japan, Europe and Canada. The Food & Drug Administration has given 510(k) clearance for MD Turbo to be marketed in the US.

Our patented i-Point™ inhalation technology used in MD Turbo® and other Respirics products allows automatic release of a dose of medication from an inhaler after the user achieves a predetermined inspiratory flow rate.

References

  1. Hampson NB, Mueller MP, Reduction in patient timing errors using a breath-actuated metered dose inhaler, Chest 1994; 106:462-65.
  2. Spiro SG, Biddiscombe M, Mariott RJ, Short M, Taylor AJ. Inspiratory flow rates attained by asthmatic patients through a metered-dose inhaler and a Diskhaler inhaler. British Journal of Clinical Research, 1992; 3:115-116
  3. Coady TJ, Davies HJ, Barnes P. Evaluation of a breath actuated pressurized aerosol. Clin Allergy 1976;6:1-6)
  4. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. CHEST 2005;127:335-371.
MD Turbo